ANI Pharmaceuticals ANIP Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's accrued expenses?
- ANI Pharmaceuticals (ANIP) reported accrued expenses of $16.09M in Q1 2026.
- How has ANI Pharmaceuticals's accrued expenses changed year-over-year?
- ANI Pharmaceuticals's accrued expenses decreased by 27.8% year-over-year, from $22.3M to $16.09M.
- What is the long-term trend for ANI Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accrued expenses has grown at a 43.5% compound annual growth rate (CAGR), from $6.23M to $37.9M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.